MARKHAM, ON, Sept. 7, 2011 /CNW/ - Cytochroma today announced that the Company will be presenting a
corporate overview at the following investor conferences:
Charles W. Bishop, Cytochroma's President and Chief Executive Officer
will be presenting at the Stifel Nicolaus Healthcare Conference 2011 at
4:25 PM ET on Wednesday, September 7, 2011 at the Four Seasons Hotel in
Eric J. Messner, Cytochroma's Chief Operating Officer will be presenting
at the RW Baird 2011 Health Care Conference at 1:45 PM ET on Thursday,
September 8, 2011 at The New York Palace Hotel in New York City.
Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and
prevent the clinical consequences of vitamin D insufficiency and
secondary hyperparathyroidism associated with chronic kidney disease
(CKD). The Company specializes in developing new therapies which are
designed to safely and effectively treat patients with stage 3, 4 or 5
CKD. Cytochroma also has a portfolio of CYP24 and phosphate-uptake
inhibitors in early stage development.
For more information about Cytochroma, please visit www.cytochroma.com.
For further information:
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
Robert Stanislaro (Financial Dynamics)
Tel: +1 (212) 850-5657